Conventional chemotherapy showed borderline significance while patients with hypomethylating agents as well as patients with myeloproliferative neoplasms had lower mortality. 43 In a meta-analysis, Vijenthira et al reported no difference in the risk for death between patients with or without ongoing systemic anticancer therapy. 36 Case reports suggest pa
← all excerpts
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.
1
—
—